Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Stock Jumps 16 Percent on Affy Settlement

NEW YORK (GenomeWeb News) - Illumina’s stock rose nearly 16 percent, to $70.02, in afternoon trading after this morning’s news that the company will settle its longstanding patent-infringement litigation with Affymetrix without admitting liability and without paying royalties.
 
Under the terms of the settlement, Illumina will pay Affy $90 million and the companies agreed to a covenant not to sue each other in the future.
 
Affymetrix’s stock, meanwhile, fell nearly 5 percent, to $22.62, from yesterday’s closing price of $23.76.
The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.